Study on the efficacy and mechanism of horticultural therapy combined with intradermal needle for the treatment of generalized anxiety in isolated personnel associated with the COVID-19 outbreak&#

Observation on the efficacy of horticultural therapy combined with intradermal needle for the treatment of generalized anxiety in isolated personnel associated with the COVID-19 epidemic during pr

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2200006846

Enrollment

Unknown

Registered

2022-12-01

Start date

2022-12-03

Completion date

Unknown

Last updated

2023-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized anxiety disorder

Interventions

intradermal needle group:Psychological care combined with intradermal needle

horticultural therapy group:Psychological care combined with horticultural therapy

Joint group:Psychological care combined with horticultural therapy and intradermal needle

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: A. Meeting the Chinese and Western medical diagnostic criteria for generalized anxiety disorder. B. Those with a GAD-7 scale score =5 and <14. C. Hamilton Anxiety Inventory (HAMA) = 7 and =21. D. No Chinese or Western medicine medication and psychotherapy, acupuncture treatment and no other trials within the last two months. E. Patients were conscious, without aphasia or mental retardation, with junior high school education or above, able to understand the content of the scale and cooperate with the treatment. F. Those who voluntarily participated in this study and signed the informed consent form.

Exclusion criteria

Exclusion criteria: A. Those who have a history of other diseases that can cause anxiety symptoms or with psychotic symptoms before enrollment, such as schizophrenia, mania, etc., and cannot cooperate with the completion of this study. B. Pregnant and lactating women. C. Aged less than 18 years or more than 70 years or older. D. Those with redness, swelling, injury, infection, etc. of the body skin and soft tissues. E. Clearly combined history of serious other systemic diseases, such as stroke, malignancy, renal failure, diabetes mellitus, cardiac insufficiency and other diseases. F. Metal allergies to nickel, chromium and other stainless steel components. G. Those who do not cooperate or reject horticultural therapy and intradermal needle treatment.

Design outcomes

Primary

Measure	Time frame
Changes in PAS 25 (response cortical LTP effect) and PAS 10 (response cortical LTD effect) in cerebral cortex;Serological indicators(corticotropin-releasing hormone\adrenocorticotropic hormone\plasma corticosterone);Assessment of relevant scales (Hamilton Anxiety Scale, Self-rating Anxiety Scale, Pittsburgh Sleep Quality Index);	—

Countries

China

Contacts

Public ContactSu guang

Suguang6633@163.com13798537716

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026